Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 5.2% – Still a Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price shot up 5.2% on Tuesday . The stock traded as high as $87.53 and last traded at $87.9450. 217,736 shares were traded during mid-day trading, a decline of 76% from the average session volume of 892,121 shares. The stock had previously closed at $83.60.

Analyst Ratings Changes

Several brokerages recently weighed in on DNTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday, March 9th. Wedbush boosted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $63.00 to $123.00 in a report on Tuesday, March 10th. Finally, TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Trading Up 1.9%

The business has a 50-day moving average price of $85.14 and a two-hundred day moving average price of $58.86. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of -20.69 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Edward Carr sold 43,682 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,021 shares of company stock valued at $26,564,008 over the last quarter. Company insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Stempoint Capital LP boosted its position in shares of Dianthus Therapeutics by 7.8% during the first quarter. Stempoint Capital LP now owns 85,502 shares of the company’s stock worth $7,175,000 after buying an additional 6,218 shares during the period. Janus Henderson Group PLC boosted its position in shares of Dianthus Therapeutics by 96.4% during the first quarter. Janus Henderson Group PLC now owns 16,500 shares of the company’s stock worth $1,384,000 after buying an additional 8,100 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Dianthus Therapeutics during the first quarter worth approximately $4,616,000. California State Teachers Retirement System boosted its position in shares of Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after buying an additional 24,697 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Dianthus Therapeutics by 847.5% during the first quarter. Royal Bank of Canada now owns 19,064 shares of the company’s stock worth $1,601,000 after buying an additional 17,052 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.